James Zangrilli

5.4k total citations · 1 hit paper
62 papers, 3.5k citations indexed

About

James Zangrilli is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, James Zangrilli has authored 62 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Physiology, 28 papers in Pulmonary and Respiratory Medicine and 16 papers in Surgery. Recurrent topics in James Zangrilli's work include Asthma and respiratory diseases (50 papers), Respiratory and Cough-Related Research (21 papers) and Eosinophilic Esophagitis (14 papers). James Zangrilli is often cited by papers focused on Asthma and respiratory diseases (50 papers), Respiratory and Cough-Related Research (21 papers) and Eosinophilic Esophagitis (14 papers). James Zangrilli collaborates with scholars based in United States, United Kingdom and Sweden. James Zangrilli's co-authors include Jorge Máspero, Guy Brusselle, Michael E. Wechsler, Mario Castro, Stephanie Korn, Christopher O’Brien, Philip G. Bardin, Eric D. Bateman, Kevin Murphy and Stephen P. Peters and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Immunology and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

James Zangrilli

60 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

2015 840 citations Mario Castro, James Zangrilli et al. The Lancet Respiratory Medicine profile →

Peers

Countries citing papers authored by James Zangrilli

Since Specialization

Citations

This map shows the geographic impact of James Zangrilli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Zangrilli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Zangrilli more than expected).

Fields of papers citing papers by James Zangrilli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Zangrilli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Zangrilli. The network helps show where James Zangrilli may publish in the future.

Co-authorship network of co-authors of James Zangrilli

This figure shows the co-authorship network connecting the top 25 collaborators of James Zangrilli. A scholar is included among the top collaborators of James Zangrilli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Zangrilli. James Zangrilli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Interleukin‐5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: Effects on and beyond eosinophils 2024 ·Allergy ·Kathleen M. Buchheit, Dominick Shaw, Geoffrey Chupp, Lauri Lehtimäki, Enrico Heffler, Tricia Finney‐Hayward, James Zangrilli, (unknown), Salman Siddiqui, Florence Roufosse, Andrew Thamboo, Nicholas P. West, (unknown), Peter W. Hellings, Anju T. Peters, Peter Howarth	21
2	Impact of season and geography on CompEx Asthma: a composite end-point for exacerbations 2020 ·ERJ Open Research ·Alexandra Jauhiainen, Lieke E.J.M. Scheepers, Anne L. Fuhlbrigge, Tim Harrison, James Zangrilli, Esther García Gil, Per Gustafson, Malin Fagerås, Carla A. Da Silva	3
3	Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma 2019 ·Annals of Allergy Asthma & Immunology ·Bradley E. Chipps, Ian Hirsch, Frank Trudo, Marianna Alacqua, James Zangrilli	29
4	Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma 2019 ·Annals of Allergy Asthma & Immunology ·Geoffrey Chupp, Njira Lugogo, Joel N. Kline, Gary T. Ferguson, Ian Hirsch, Mitchell Goldman, James Zangrilli, Frank Trudo	12
5	Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies 2017 ·The Lancet Respiratory Medicine ·J. Mark FitzGerald, Eugene R. Bleecker, Andrew Menzies‐Gow, James Zangrilli, Ian Hirsch, Paul Metcalfe, Paul Newbold, Mitchell Goldman	225
6	Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma 2016 ·CHEST Journal ·Jonathan Corren, Steven F. Weinstein, Lindsay Janka, James Zangrilli, Margaret Garin	299
7	Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials breakdown → 2015 ·The Lancet Respiratory Medicine ·Mario Castro, James Zangrilli, Michael E. Wechsler, Eric D. Bateman, Guy Brusselle, Philip G. Bardin, Kevin Murphy, Jorge Máspero, Christopher O’Brien, Stephanie Korn	840
8	A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma 2014 ·European Respiratory Journal ·Jonathan Corren, Steven F. Weinstein, Lindsay Janka, Christopher O’Brien, James Zangrilli	13
9	The Effect of Budesonide/Formoterol Pressurized Metered-Dose Inhaler on Predefined Criteria for Worsening Asthma in Four Different Patient Populations with Asthma 2012 ·Drugs in R&D ·Kevin R. Murphy, Tom Uryniak, Ubaldo J. Martin, James Zangrilli	3
10	Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and β2-agonist use 2006 ·Respiratory Research ·Annette T. Hastie, Min Wu, (unknown), Gregory A. Hawkins, Vikas Batra, Katherine A. Rybinski, (unknown), James Zangrilli, Stephen P. Peters	7
11	Bronchoalveolar lavage fluid concentrations of transforming growth factor (TGF)‐β1, TGF‐β2, interleukin (IL)‐4 and IL‐13 after segmental allergen challenge and their effects on α‐smooth muscle actin and collagen III synthesis by primary human lung fibroblasts 2004 ·Clinical & Experimental Allergy ·Vikas Batra, Ali I. Musani, Annette T. Hastie, Sandhya Khurana, (unknown), James Zangrilli, Stephen P. Peters	159
12	Differential Expression of TRAIL and TRAIL Receptors in Allergic Asthmatics Following Segmental Antigen Challenge: Evidence for a Role of TRAIL in Eosinophil Survival 2002 ·The Journal of Immunology ·Noreen M. Robertson, James Zangrilli, Andrzej Steplewski, Annette T. Hastie, (unknown), (unknown), (unknown), Nathalie Innocent, Ali I. Musani, Rodolfo M. Pascual, Stephen P. Peters, Gerald Litwack	65
13	Asthmatic Epithelial Cell Proliferation and Stimulation of Collagen Production: Human Asthmatic Epithelial Cells Stimulate Collagen Type III Production by Human Lung Myofibroblasts after Segmental Allergen Challenge 2002 ·American Journal of Respiratory and Critical Care Medicine ·Annette T. Hastie, Walter K. Kraft, (unknown), James Zangrilli, Ali I. Musani, James E. Fish, Stephen P. Peters	48
14	Distinction between IL-13+ and IFN-γ+ natural killer cells and regulation of their pool size by IL-4 2002 ·European Journal of Immunology ·Matthew J. Loza, Stephen P. Peters, James Zangrilli, B Perussia	36
15	Regulation of Eosinophil Viability by Cytokines 2002 ·American Journal of Respiratory Cell and Molecular Biology ·James Zangrilli	8
16	Kinetics of IL-10 production after segmental antigen challenge of atopic asthmatic subjects 2000 ·Journal of Allergy and Clinical Immunology ·(unknown), Annette T. Hastie, Ali I. Musani, Rodolfo M. Pascual, (unknown), (unknown), (unknown), James Zangrilli, James E. Fish, Stephen P. Peters	29
17	Kinetics of the Development and Recovery of the Lung From IgE-Mediated Inflammation: Dissociation of Pulmonary Eosinophilia, Lung Injury, and Eosinophil-Active Cytokines 1997 ·American Journal of Respiratory and Critical Care Medicine ·Joseph R. Shaver, James Zangrilli, (unknown), (unknown), Mary Pollice, Annette T. Hastie, James E. Fish, Stephen P. Peters	55
18	IL-1β RELEASE FROM CULTURED BRONCHIAL EPITHELIAL CELLS AND BRONCHOALVEOLAR LAVAGE CELLS FROM ALLERGIC AND NORMAL HUMANS FOLLOWING SEGMENTAL CHALLENGE WITH RAGWEED 1996 ·Cytokine ·Annette T. Hastie, (unknown), (unknown), James Zangrilli, Joseph R. Shaver, Mary Pollice, James E. Fish, Stephen P. Peters	32
19	SVCAM-1 Levels after Segmental Antigen Challenge Correlate with Eosinophil Influx, IL-4 and IL-5 Production, and the Late Phase Response 1995 ·American Journal of Respiratory and Critical Care Medicine ·James Zangrilli, Joseph R. Shaver, (unknown), (unknown), Charles G. Garlisi, Angela Falcone, Francis M. Cuss, James E. Fish, Stephen P. Peters	87
20	Eosinophils recruited to the lung by segmental antigen challenge show a reduced chemotactic response to leukotriene B4 1994 ·Prostaglandins ·(unknown), Gregory C. Kane, James Zangrilli, (unknown), Young Yull Koh, Stephen P. Peters	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact